Why the study?
Does intravenous amiodarone successfully cardiovert atrial flutter in a newborn?
Does intravenous amiodarone successfully cardiovert atrial flutter in a newborn?
Intravenous amiodarone may be an effective pharmacological therapy for neonatal atrial flutter in hemodynamically stable patients.
Amiodarone efficacy for neonatal atrial flutter remains unknown; leaves open need for prospective trials before clinical adoption.
Atrial flutter is an uncommon arrhythmia in newborn patients, but it can be fatal in intractable cases, which require emergent therapy with multiple antiarrhythmic therapies and an electrical cardioversion. Amiodarone is an antiarrhythmic drug commonly used to treat tachyarrhythmias of supraventricular tachycardia and atrial tachyarrhythmia in adults. The efficacy of amiodarone therapy for neonatal tachyarrhythmia including atrial flutter is currently unknown, but its estimated effectiveness is low with small experiences in neonates. We present a case of successful pharmacologic cardioversion, using intravenous amiodarone, of atrial flutter and did not require electrical cardioversion in a newborn. We suggest that intravenous amiodarone administration can be used to treat neonatal atrial flutter as effective pharmacological therapy in patient with hemodynamic stability.
No takes yet. Share an insight, caveat, or question.
Yun Ju Lim (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: